Single-Use Bioreactors Market to Reach US$ 9.12 Billion by 2033 as Biopharmaceutical Manufacturing Accelerates Worldwide

DataM Intelligence has released a new research report titled "Single-use Bioreactors Market Size 2026". The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the global Single-use Bioreactors Market.

Get a Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/single-use-bioreactors-market?ram

The global single-use bioreactors market reached US$ 4.30 billion in 2023, with a rise to US$ 4.64 billion in 2024, and is expected to reach US$ 9.12 billion by 2033, growing at a CAGR of 8.8% during the forecast period 2025-2033.

The market is witnessing significant growth due to the increasing adoption of biopharmaceutical manufacturing, rising demand for personalized medicines, and expanding use of single-use technologies in vaccine production and cell culture applications. Pharmaceutical and biotechnology companies are increasingly shifting toward flexible and cost-efficient bioprocessing systems to reduce contamination risks and improve operational efficiency.

Industry participants are focusing on scalable and automated single-use bioreactor systems to support rapid production cycles, lower capital investment requirements, and enhanced process flexibility. Growing investments in biologics, biosimilars, and advanced therapeutic development are expected to create long-term opportunities for manufacturers, technology providers, and contract development and manufacturing organizations worldwide.

Key Industry Developments

United States:
✅ April 2026: Sartorius reported strong growth in its Bioprocess Solutions division, driven by increasing adoption of advanced single-use bioreactor technologies and flexible biologics manufacturing systems. The company also highlighted expanded sustainable bioprocessing capabilities using renewable raw materials compatible with existing single-use platforms.

✅ January 2026: Thermo Fisher Scientific expanded its single-use bioprocessing innovation initiatives, supporting advanced biologics and vaccine manufacturing with scalable DynaDrive bioreactor technologies. The company emphasized process intensification, reduced contamination risks, and faster therapy commercialization through next-generation disposable bioreactor systems.

✅ December 2025: Cytiva completed major bioprocess manufacturing and capacity expansion projects across the United States to strengthen supply of single-use bioreactor and filtration technologies. The investments focused on improving production flexibility, accelerating biologics scale-up, and supporting growing demand from CDMOs and biopharma companies.

Japan:
✅ December 2025: FUJIFILM Corporation completed one of Japan's largest bio-CDMO facilities at its Toyama site, integrating advanced 5,000 L single-use mammalian cell culture bioreactors. The new facility strengthens Japan's biologics manufacturing infrastructure and supports antibody drug and ADC production using modular bioprocessing technologies.

✅ November 2025: FUJIFILM Diosynth Biotechnologies advanced its modular "kojoXTM" manufacturing approach to standardize single-use bioreactor operations and accelerate technology transfer across global facilities. The initiative was designed to improve manufacturing efficiency, scalability, and rapid deployment for biopharmaceutical production.

✅ October 2025: CP Biotools showcased a novel low-shear single-use perfusion bioreactor technology during international biomanufacturing discussions involving Japanese biopharma stakeholders and researchers. The development focused on reducing operational costs, improving cell viability, and enhancing continuous bioprocessing performance for next-generation biologics manufacturing.

Strategic Acquisitions & Partnerships
✅ Sartorius AG - Expansion
(January, 2026)
Sartorius announced the expansion of its bio-circular product portfolio for biopharma manufacturers, adding more sustainable single-use fluid management technologies and filters to support environmentally conscious bioprocessing operations. The initiative strengthens the company's position in the single-use bioreactors and bioprocessing ecosystem by addressing sustainability and operational efficiency demands from biologics manufacturers.

✅ Thermo Fisher Scientific - Expansion
(December, 2025)
Thermo Fisher Scientific expanded its bioprocess design centers across Asia, including facilities in Hyderabad, Incheon, and Singapore, to support advanced single-use bioprocessing and biologics manufacturing. The expansion was designed to help regional biopharma companies accelerate development and scale-up of vaccines and biologic therapies using single-use technologies.

Key Players:
ABEC | Thermo Fisher Scientific | Sartorius AG | Celltainer | Distek, Inc. | Merck KGaA | PBS Biotech, Inc. | Cytiva | Eppendorf SE | Getinge AB

Key Highlights: Top 5 Key Players in Single-use Bioreactors Market 2026
-Thermo Fisher Scientific: Expanded its bioprocessing portfolio with the launch of the 5L DynaDrive Single-Use Bioreactor, designed to accelerate bench-scale process development and provide seamless scalability from 1 L to 5,000 L. The system delivers improved cell culture productivity, enhanced gas transfer performance, and integration with advanced process analytical technologies for intensified biologics manufacturing.

-Sartorius AG: Strengthened upstream bioprocessing capabilities through the Biostat STR Generation 3 platform with integrated automation and intensified processing support. The latest system enhancements include integrated Repligen XCell ATF technology, DeltaV automation compatibility, and modular seed train configurations to improve scalability, operational flexibility, and continuous biomanufacturing efficiency.

-Cytiva: Expanded the Xcellerx X-platform bioreactor portfolio with new 500 L and 2,000 L single-use bioreactors to support scale-up of advanced therapeutics manufacturing. The upgraded platform enhances production efficiency with ergonomic designs, automated foam detection, flexible scale-out capability, and streamlined supply chain operations for commercial biologics manufacturing.

-Merck KGaA: Advanced single-use bioprocessing innovation through its Mobius bioreactor portfolio by focusing on integrated upstream manufacturing workflows, process intensification, and contamination risk reduction. The company continues enhancing single-use solutions with automation-ready systems and scalable bioprocess technologies tailored for cell and gene therapy production.

-Eppendorf SE: Continued strengthening flexible bioprocess development with its single-use bioreactor systems featuring advanced sensor integration, scalable stirred-tank designs, and automated process control capabilities. The company's recent focus has been on improving reproducibility and accelerating biologics process optimization for research and pilot-scale applications.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/single-use-bioreactors-market?ram

Main Drivers and Trends Shaping the Future of the Single-use Bioreactors Market
-Biopharmaceutical Expansion: Rising demand for biologics, monoclonal antibodies, vaccines, and cell & gene therapies is accelerating the adoption of single-use bioreactors across biopharmaceutical manufacturing facilities.

-Faster and Flexible Production: Single-use systems reduce cleaning validation requirements, minimize contamination risks, and enable rapid batch changeovers, supporting flexible and cost-efficient production processes.

-Growth in Contract Manufacturing: Increasing reliance on CDMOs and CROs is driving demand for disposable bioprocessing technologies that support scalable production and multi-product manufacturing environments.

-Technological Advancements: Integration of automation, real-time monitoring sensors, advanced control software, and hybrid bioprocessing systems is improving process efficiency, scalability, and operational reliability.

-Sustainability and Cost Optimization: Manufacturers are focusing on reducing water and energy consumption, lowering operational costs, and improving production efficiency, while addressing challenges related to plastic waste management and supply chain dependence for disposable components.

Regional Insights:
-North America: 34.24% (Largest market share, driven by strong biopharmaceutical manufacturing infrastructure, high R&D investments, and rapid adoption of disposable bioprocessing technologies in the U.S. and Canada).

-Europe: 20.4% (Supported by advanced biotech ecosystems, biosimilar production growth, and increasing integration of sustainable single-use manufacturing systems).

-Asia Pacific: 18.9% (Fastest-growing region, fueled by expanding biologics manufacturing facilities and heavy investments across China, India, South Korea, Singapore, and Japan).

Purchase Corporate License | Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=single-use-bioreactors-market?ram

Market Segmentation Analysis:
-By Product: Single-use Bioreactor Systems Lead Due to Flexible Bioprocessing
Single-use bioreactor systems are widely adopted for upstream bioprocessing because they reduce contamination risks, lower cleaning requirements, and improve operational flexibility in biologics manufacturing.
Single-use media bags support sterile storage and transport of media and buffers, gaining importance in continuous bioprocess workflows.
Single-use filtration assemblies are increasingly used for purification and separation processes due to their efficiency and disposable design, while other accessories support integrated biomanufacturing operations.

-By Type: Stirred Tank Single-use Bioreactors Dominate Industrial Applications
Stirred tank single-use bioreactors are preferred for large-scale commercial biologics production because of efficient mixing, scalability, and strong process control.
Wave-induced systems are widely utilized in seed culture and small-batch production owing to gentle mixing and low shear stress.
Bubble column single-use bioreactors are gaining attention in specialized cell culture applications requiring simplified aeration systems.

-By Molecule Type: Monoclonal Antibodies Remain Key Revenue Contributor
Monoclonal antibodies represent a major application area due to rising demand for targeted biologics and immunotherapies.
Vaccines continue to drive adoption with increasing global focus on rapid and scalable vaccine manufacturing capabilities.
Stem cells and gene-modified cells are witnessing growing use in regenerative medicine and cell therapy research, while other molecules support expanding biopharmaceutical pipelines.

-By Cell Type: Mammalian Cells Hold Strong Preference in Biologics Production
Mammalian cells dominate because they enable complex protein expression required for monoclonal antibodies and advanced therapeutics.
Bacteria cells are extensively used for rapid microbial fermentation and recombinant protein production.
Yeast cells offer advantages in cost-effective bioprocessing and vaccine manufacturing, while other cell types support niche biopharmaceutical and research applications.

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTW

Contact:
Fabian
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, DataM Intelligence 4market Research LLP, Lalitha Nagar, Habsiguda, Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
UK: +44 161-870-5507
Email: fabian@datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to provide swift and astute solutions to clients like you. We encompass a multitude of syndicated reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.